EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSMLUG00000008026
Gene Symbol: PIK3CD
2 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSMLUG00000002568
Gene Symbol: PIK3CG
2 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSMLUG00000006020
Gene Symbol: PDE10A
2 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSMLUG00000017228
Gene Symbol: PDE3A
2 Cross references
272 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSMLUG00000009266
Gene Symbol: PDE3B
2 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSMLUG00000015123
Gene Symbol: PDE4A
2 Cross references
275 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSMLUG00000009026
Gene Symbol: PDE4B
2 Cross references
292 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSMLUG00000003985
Gene Symbol: PDE4C
2 Cross references
269 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSMLUG00000016574
Gene Symbol: PDE4D
2 Cross references
240 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSMLUG00000016073
Gene Symbol: PDE7A
2 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSMLUG00000002323
Gene Symbol: PDE7B
2 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSMLUG00000024657
Gene Symbol: PDE9A
2 Cross references
280 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).